Sidney Kimmel Comprehensive Cancer Center At Thomas Jefferson University

This study is testing a specialized, targeted form of radiation therapy for people with newly diagnosed brain tumors (gliomas). The goal is to see if this precise method can effectively treat the tumor while causing fewer side effects to the scalp, such as infections, poor wound …

This study is testing whether taking one of two oral medications—sunitinib or valproic acid—for 6 to 12 months can help prevent a high-risk form of eye melanoma from spreading to other parts of the body after initial treatment. It involves 210 patients who have already had their …

This early-stage study aimed to find the safest and most effective dose of the chemotherapy drug bendamustine for people with multiple myeloma who had been treated before. Researchers planned to give increasing doses to small groups of patients to see how much they could tolerate…

This study aimed to see if adding a drug called temsirolimus (Torisel) to standard chemotherapy and radiation was safe for people with advanced head and neck cancer. It was designed to find the highest dose of temsirolimus that could be given safely alongside the usual treatments…

This study is testing whether a 7-day course of the drug linaclotide can produce biological changes in colon polyps or early-stage colorectal tumors. About 230 patients scheduled for a colonoscopy or surgery will take either linaclotide or a placebo pill daily for one week before…

This study aims to determine if combining two targeted radiation treatments is safe for men with intermediate-risk prostate cancer. The approach involves a brief internal radiation treatment followed by a shorter, more precise external radiation course over three weeks. Researche…

This study is testing how well two targeted drugs, obinutuzumab and ibrutinib, work together as the first treatment for people with certain slow-growing types of non-Hodgkin's lymphoma. The goal is to control the cancer by stopping cancer cells from growing and spreading, potenti…